Hearing aid use linked to better cognition in hearing-impaired elderly

  • A study of older adults with impaired hearing supports the use of hearing aids to help fight the development of cognitive decline and dementia.

A study involving 100 older adults (aged 80-99) with hearing loss has found that those who used a hearing aid performed significantly better on a cognitive test (MMSE) than those who didn't use a hearing aid, despite having poorer hearing. Among non-users, participants with more hearing loss had lower MMSE scores than those with better hearing.

In the MMSE, participants give vocal responses to verbal commands. Executive function was also assessed with the Trail Making Test, Part B, which doesn't have a verbal or auditory component. On this test, although hearing aid users performed better than non-users, the difference was not statistically significant. Nor were scores correlated with hearing level.

The finding suggests that hearing loss is associated with sensory-specific cognitive decline rather than global cognitive impairment.

Of the 100 participants, 34 regularly used a hearing aid.

Previous studies have found hearing loss is associated with greater cognitive decline in older adults. A physician recently told the annual meeting of the American Association for the Advancement of Science (AAAS) that as much as 36% of dementia risk might be attributable to hearing impairment, and urged that doctors treat age-related hearing impairment more seriously.

The finding supports the view that use of hearing aids for the hearing impaired may help keep them more socially engaged, thus preventing or slowing the progression of cognitive decline and the development of dementia.

More than half of adults over age 75 have hearing loss, yet less than 15% of the hearing impaired use a hearing aid.

http://www.eurekalert.org/pub_releases/2016-04/cumc-hau042216.php

Reference: 

Related News

Two studies help explain why kidney disease increases the risk of cardiovascular diseases such as high blood pressure and vascular calcification. The mediator seems to be a hormone called FGF23, which is sensitive to the level of phosphates in the body.

A study in which 157 healthy adult volunteers were asked to regulate their emotional reactions to unpleasant pictures, has found that those who showed greater brain activation when regulating their negative emotions also had higher blood levels of interleukin-6 (a marker for inflammation) and in

A finding that free radicals promote longevity in the roundworm challenges the theory that free radicals (oxidants) are damaging and cause aging.

A study involving 614 patients with type 2 diabetes (mean age 62) has found that longer duration of diabetes was associated with more brain volume loss, particularly in the gray matter.

Type 2 diabetes greatly increases a person's risk of developing cardiovascular disease, but a new study shows that cardiovascular risk factors such as elevated blood pressure and cholesterol levels differ significantly between men and women with diabetes.

A mouse study has found that introduction of oral bacteria into the bloodstream increased risk factors for atherosclerotic heart disease, including cholesterol and inflammation, suggesting that the same bacteria that cause gum disease also promotes heart disease.

A large study, involving 3,690 older adults, has found that drugs with strong anticholinergic effects cause memory and cognitive impairment when taken continuously for a mere two months.

A new study adds to growing evidence of a link between sleep problems and Alzheimer’s. The interesting thing is that this association – between sleep apnea and Alzheimer’s biomarkers — wasn’t revealed until the data was separated out according to BMI.

Family caregivers of dementia sufferers who are reluctant to use adult day care services might like to note the findings of a telephone survey. The study involved eight daily telephone interviews on consecutive days with 173 family caregivers who use an ADS on some days.

Last year, a cancer drug, Bexarotene, was touted as a potential treatment for Alzheimer’s disease. However, four independent studies have now failed to replicate the most dramatic result of the original study: a claim that the drug could clear half the amyloid plaques in a mere 72 hours.

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health news